{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:50:50Z","timestamp":1791568250222,"version":"4.3.4"},"reference-count":93,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.nefroe.2026.501553","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:55:46Z","timestamp":1791564946000},"page":"501553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-CD20 monoclonal antibodies in membranous nephropathy"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0739-0449","authenticated-orcid":false,"given":"Juan Daniel","family":"D\u00edaz-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0633-6325","authenticated-orcid":false,"given":"Avinash Chandu","family":"Nanwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7979-5054","authenticated-orcid":false,"given":"Arturo Villalobos","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9855-2545","authenticated-orcid":false,"given":"Enrique Jos\u00e9 Antonio Robiou","family":"Vivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9647-2778","authenticated-orcid":false,"given":"Eduardo Guerrero","family":"Hinzpeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence H.","family":"Beck Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7582-8476","authenticated-orcid":false,"given":"Luis Fernando","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2026.501553_bib0465","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3390\/jcm14030761","article-title":"Membranous nephropathy","volume":"14","author":"Ponticelli","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.nefroe.2026.501553_bib0470","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.ajkd.2023.08.010","article-title":"Ofatumumab in rituximab-resistant and rituximab-intolerant patients with primary membranous nephropathy: a case series","volume":"83","author":"Podest\u00e0","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2026.501553_bib0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100853","article-title":"Obinutuzumab in refractory membranous nephropathy: a case series","volume":"6","author":"Lin","year":"2024","journal-title":"Kidney Med"},{"key":"10.1016\/j.nefroe.2026.501553_bib0480","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf026","article-title":"Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy","volume":"18","author":"Su","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2026.501553_bib0485","article-title":"Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study","volume":"16","author":"Cheng","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0490","article-title":"Experience with new anti-CD20 monoclonal antibodies for immune-mediated glomerulopathies in a tertiary hospital","author":"Zamora","year":"2025","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2026.501553_bib0495","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/ki.2010.34","article-title":"Membranous nephropathy: recent travels and new roads ahead","volume":"77","author":"Beck","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2026.501553_bib0500","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.kint.2016.09.048","article-title":"Membranous nephropathy: integrating basic science into improved clinical management","volume":"91","author":"Cattran","year":"2017","journal-title":"Kidney Int"},{"issue":"4S","key":"10.1016\/j.nefroe.2026.501553_bib0505","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2026.501553_bib0510","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/s41581-025-00980-z","article-title":"Antigens in membranous nephropathy: discovery and clinical implications","volume":"21","author":"Sethi","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0520","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/ndt\/gfaa014","article-title":"The evolution of the therapeutic approach to membranous nephropathy","volume":"36","author":"Ponticelli","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2026.501553_bib0525","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.3390\/medicina59111997","article-title":"How to choose the right treatment for membranous nephropathy","volume":"59","author":"Peritore","year":"2023","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"10.1016\/j.nefroe.2026.501553_bib0530","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJM198901053200102","article-title":"A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy","volume":"320","author":"Ponticelli","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2026.501553_bib0535","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","article-title":"A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy","volume":"9","author":"Ponticelli","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0540","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/ndt\/gfad225","article-title":"Membranous nephropathy treatment standard","volume":"39","author":"Radhakrishnan","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2026.501553_bib0545","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1007\/s11255-025-04549-4","volume":"57","author":"Cai","year":"2025","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0550","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.4049\/jimmunol.125.4.1678","article-title":"Characterization of a human B lymphocyte-specific antigen","volume":"125","author":"Stashenko","year":"1980","journal-title":"J Immunol (Baltimore, Md.: 1950)"},{"key":"10.1016\/j.nefroe.2026.501553_bib0555","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/icb.2015.48","article-title":"The MS4A family: counting past 1, 2 and 3","volume":"94","author":"Eon Kuek","year":"2016","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0560","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.4049\/jimmunol.142.7.2560","article-title":"Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1)","volume":"142","author":"Tedder","year":"1989","journal-title":"J Immunol (Baltimore, Md.: 1950)"},{"key":"10.1016\/j.nefroe.2026.501553_bib0565","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1016\/S0021-9258(19)81618-6","article-title":"Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes","volume":"263","author":"Tedder","year":"1988","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nefroe.2026.501553_bib0570","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1083\/jcb.121.5.1121","article-title":"Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes","volume":"121","author":"Bubien","year":"1993","journal-title":"J Cell Biol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0575","doi-asserted-by":"crossref","first-page":"18545","DOI":"10.1074\/jbc.M800784200","article-title":"CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins","volume":"283","author":"Polyak","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nefroe.2026.501553_bib0580","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.4049\/jimmunol.157.7.2939","article-title":"Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY","volume":"157","author":"Sz\u00f6ll\u00f3si","year":"1996","journal-title":"J Immunol (Baltimore, Md.: 1950)"},{"key":"10.1016\/j.nefroe.2026.501553_bib0585","article-title":"B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets","volume":"11","author":"Forsthuber","year":"2018","journal-title":"Therap Adv Neurol Disord"},{"key":"10.1016\/j.nefroe.2026.501553_bib0590","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","article-title":"Mechanisms of killing by anti-CD20 monoclonal antibodies","volume":"44","author":"Glennie","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0595","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.nefroe.2026.501553_bib0600","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20: a regulator of cell-cycle progression of B lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol Today"},{"key":"10.1016\/j.nefroe.2026.501553_bib0605","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.nefroe.2026.501553_bib0610","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1172\/JCI40231","article-title":"CD20 deficiency in humans results in impaired T cell-independent antibody responses","volume":"120","author":"Kuijpers","year":"2010","journal-title":"J Clin Investig"},{"key":"10.1016\/j.nefroe.2026.501553_bib0615","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/intimm\/dxh009","article-title":"Mouse CD20 expression and function","volume":"16","author":"Uchida","year":"2004","journal-title":"Int Immunol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0620","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3389\/fimmu.2017.01245","article-title":"Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going?","volume":"8","author":"Marshall","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0625","first-page":"676","article-title":"Mechanisms of action of CD20 antibodies","volume":"2","author":"Boross","year":"2012","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.nefroe.2026.501553_bib0630","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"mAbs"},{"key":"10.1016\/j.nefroe.2026.501553_bib0635","article-title":"Complement-dependent activity of CD20-specific IgG correlates with bivalent antigen binding and C1q binding strength","volume":"11","author":"Bondza","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0640","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1158\/2326-6066.CIR-18-0319","article-title":"Cellular cytotoxicity of next-generation CD20 monoclonal antibodies","volume":"6","author":"VanDerMeid","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.nefroe.2026.501553_bib0645","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fern\u00e1ndez-Ju\u00e1rez","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2026.501553_bib0650","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0655","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0660","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0665","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2026.501553_bib0670","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0675","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s40360-025-00954-8","article-title":"Efficacy and safety of a B-cell-driven rituximab regimen for the treatment of refractory idiopathic membranous nephropathy","volume":"26","author":"Guo","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0680","doi-asserted-by":"crossref","first-page":"e093920","DOI":"10.1136\/bmjopen-2024-093920","article-title":"Artificial intelligence-based personalised rituximab treatment protocol in membranous nephropathy (iRITUX): protocol for a multicentre randomised control trial","volume":"15","author":"Teisseyre","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.nefroe.2026.501553_bib0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108635","article-title":"Novel treatment options in rituximab-resistant membranous nephropathy patients","volume":"107","author":"Ahmadian","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0690","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.3389\/fimmu.2019.03069","article-title":"Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab","volume":"10","author":"Boyer-Suavet","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.nefroe.2026.501553_bib08751","doi-asserted-by":"crossref","first-page":"529","DOI":"10.4049\/jimmunol.2300647","article-title":"Cross-reactivity of antibodies to rituximab with other therapeutic anti-CD20 antibodies","volume":"212","author":"Rispens","year":"2024","journal-title":"J Immunol (Baltimore, Md.: 1950)"},{"key":"10.1016\/j.nefroe.2026.501553_bib0695","first-page":"160","article-title":"New treatments in membranous glomerulopathy \u2013 from the pitfalls of rituximab to a new era of biological treatments","volume":"34","author":"Ferreira","year":"2020","journal-title":"Port J Nephrol Hypertens"},{"key":"10.1016\/j.nefroe.2026.501553_bib0700","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1060028018803587","article-title":"Rituximab exhibits altered pharmacokinetics in patients with membranous nephropathy","volume":"53","author":"Fogueri","year":"2019","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.nefroe.2026.501553_bib05151","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.nefroe.2026.501553_bib0705","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5414\/CNP88FX07","article-title":"Rituximab for the treatment of membranous nephropathy: a single-center experience","volume":"88","author":"Ale\u0161 Rigler","year":"2017","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nefroe.2026.501553_bib07351","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/j.ajkd.2020.02.444","article-title":"Successful treatment of patients with refractory PLA2R-associated membranous nephropathy with obinutuzumab: a report of 3 cases","volume":"76","author":"Klomjit","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2026.501553_bib0710","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.nefroe.2026.501553_bib0715","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Mol Cancer Therap"},{"key":"10.1016\/j.nefroe.2026.501553_bib0720","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1182\/blood-2010-07-298356","article-title":"The future of anti-CD20 monoclonal antibodies: are we making progress?","volume":"117","author":"Alduaij","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.nefroe.2026.501553_bib0725","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2026.501553_bib0730","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1681\/ASN.2017040367","article-title":"Targeting B cells and plasma cells in glomerular diseases: translational perspectives","volume":"29","author":"Schrezenmeier","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0740","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.ekir.2024.05.004","article-title":"Obinutuzumab as initial or second-line therapy in patients with primary membranous nephropathy","volume":"9","author":"Su","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2026.501553_bib0745","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.2215\/CJN.0000000000000555","article-title":"Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy","volume":"19","author":"Hu","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0750","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/ndt\/gfae230","article-title":"Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy","volume":"40","author":"Xu","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2026.501553_bib0755","first-page":"1","article-title":"Additive obinutuzumab achieves high remission rates in rituximab-refractory membranous nephropathy","author":"Li","year":"2025","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0760","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.ekir.2020.06.030","article-title":"Obinutuzumab is effective for the treatment of refractory membranous nephropathy","volume":"5","author":"Sethi","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2026.501553_bib0765","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12882-022-02761-3","article-title":"Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases","volume":"23","author":"Hudson","year":"2022","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0770","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.2147\/DDDT.S527661","article-title":"Obinutuzumab is effective as an initial treatment for PLA2R-associated primary membranous nephropathy: a retrospective, single-center trial","volume":"19","author":"Li","year":"2025","journal-title":"Drug Des Dev Therapy"},{"key":"10.1016\/j.nefroe.2026.501553_bib0910","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s11255-025-04407-3","article-title":"Observation of the efficacy and safety of obinutuzumab in the treatment of refractory idiopathic membranous nephropathy","volume":"57","author":"Li","year":"2025","journal-title":"Int Urol Nephrol."},{"key":"10.1016\/j.nefroe.2026.501553_bib0775","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1080\/21645515.2018.1508624","article-title":"Anti-CD20 monoclonal antibodies: reviewing a revolution","volume":"14","author":"Casan","year":"2018","journal-title":"Hum Vacc Immunother"},{"key":"10.1016\/j.nefroe.2026.501553_bib0780","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s40120-023-00518-0","article-title":"The development of ofatumumab, a fully human anti-CD20 monoclonal antibody for practical use in relapsing multiple sclerosis treatment","volume":"12","author":"Hauser","year":"2023","journal-title":"Neurol Therapy"},{"key":"10.1016\/j.nefroe.2026.501553_bib0785","doi-asserted-by":"crossref","first-page":"e232896","DOI":"10.1136\/bcr-2019-232896","article-title":"Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness","volume":"13","author":"Podest\u00e0","year":"2020","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.nefroe.2026.501553_bib0790","article-title":"Case Report: Subcutaneous ofatumumab for patients with immunosuppressant-dependent or ineffective primary membranous nephropathy","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0795","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.ekir.2024.12.012","article-title":"Obinutuzumab and ofatumumab are more effective than rituximab in the treatment of membranous nephropathy patients with anti-rituximab antibodies","volume":"10","author":"Teisseyre","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2026.501553_bib0800","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1024068","article-title":"Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives","volume":"13","author":"Hartinger","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0805","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/annonc\/mdq027","article-title":"Results of a phase I\/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed\/refractory follicular lymphoma","volume":"21","author":"Morschhauser","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0810","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40620-020-00874-2","article-title":"Successful treatment of PLA2R1-antibody positive membranous nephropathy with ocrelizumab","volume":"34","author":"Schmidt","year":"2021","journal-title":"J Nephrol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0815","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.788830","article-title":"Systematic review of safety and efficacy of second- and third-generation CD20-targeting biologics in treating immune-mediated disorders","volume":"12","author":"Kaegi","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0915","doi-asserted-by":"crossref","first-page":"1741564","DOI":"10.3389\/fimmu.2025.1741564","article-title":"Efficacy and safety of zuberitamab in the treatment of primary membranous nephropathy: an observational study","volume":"16","author":"Zong","year":"2026","journal-title":"Front Immunol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0820","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/ckj\/sfad075","article-title":"Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy","volume":"16","author":"Zand","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2026.501553_bib0825","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2017.92","article-title":"Treatment of membranous nephropathy: time for a paradigm shift","volume":"13","author":"Ruggenenti","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0830","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","article-title":"Pathophysiological advances in membranous nephropathy: time for a shift in patient's care","volume":"385","author":"Ronco","year":"2015","journal-title":"Lancet (Lond, Engl)"},{"key":"10.1016\/j.nefroe.2026.501553_bib0835","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.3390\/ijerph19095301","article-title":"The role of anti-PLA2R and anti-THSD7A antibodies in the pathogenesis and diagnostics of primary membranous nephropathy: a review of current knowledge for clinical practice","volume":"19","author":"Smarz-Widelska","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.nefroe.2026.501553_bib0840","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0845","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2215\/CJN.0000000000000237","article-title":"Anti-PLA2R antibody levels and clinical risk factors for treatment nonresponse in membranous nephropathy","volume":"18","author":"Barbour","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0850","doi-asserted-by":"crossref","first-page":"e0173201","DOI":"10.1371\/journal.pone.0173201","article-title":"Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: a single-centre study over 14 years","volume":"12","author":"Pourcine","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.nefroe.2026.501553_bib0855","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112769","article-title":"B cell dysregulation and depletion therapy in primary membranous nephropathy: prospects and potential challenges","volume":"140","author":"Wu","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0860","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.kint.2017.01.012","article-title":"B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab","volume":"92","author":"Rosenzwajg","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2026.501553_bib0865","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1598197","article-title":"The role of B lymphocyte subsets in nephrotic syndrome: functions, mechanisms, clinical significance and future perspectives","volume":"16","author":"Liao","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0870","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/7651024","article-title":"Circulating (CD3(\u2212)CD19(+)CD20(\u2212)IgD(\u2212)CD27(high)CD38(high)) plasmablasts: a promising cellular biomarker for immune activity for anti-PLA2R1 related membranous nephropathy?","volume":"2016","author":"Pozdzik","year":"2016","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.nefroe.2026.501553_bib09101","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0920","doi-asserted-by":"crossref","first-page":"e184169","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.nefroe.2026.501553_bib0880","doi-asserted-by":"crossref","DOI":"10.5500\/wjt.v15.i4.108982","article-title":"Obinutuzumab in kidney transplantation: past, present, and future","volume":"15","author":"Favi","year":"2025","journal-title":"World J Transplant"},{"key":"10.1016\/j.nefroe.2026.501553_bib0885","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s40620-025-02224-6","article-title":"Obinutuzumab in rituximab-resistant and recurrent membranous nephropathy: a case-series","volume":"38","author":"Sridharan","year":"2025","journal-title":"J Nephrol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0890","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adm8186","article-title":"Chimeric autoantibody receptor T cells clonally eliminate B cells producing autoantibodies against IFN-\u03b3","volume":"10","author":"Peng","year":"2025","journal-title":"Sci Immunol"},{"key":"10.1016\/j.nefroe.2026.501553_bib0895","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Investig"},{"key":"10.1016\/j.nefroe.2026.501553_bib0900","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.kint.2024.01.021","article-title":"An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells","volume":"105","author":"Seifert","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2026.501553_bib0905","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.kint.2025.09.028","article-title":"Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T cells","volume":"109","author":"Altun","year":"2026","journal-title":"Kidney Int"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S201325142600163X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S201325142600163X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:56:19Z","timestamp":1791564979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S201325142600163X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":93,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S201325142600163X"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2026.501553","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-CD20 monoclonal antibodies in membranous nephropathy","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2026.501553","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501553"}}